Sec Form 4 Filing - Piscitelli Dominic @ Oric Pharmaceuticals, Inc. - 2022-07-20

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Piscitelli Dominic 2. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ ORIC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 07/20/2022 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 6.44 07/20/2022 D 207,500 ( 1 ) 09/10/2029 Common Stock 207,500 ( 2 ) 0 D Stock Option (right to buy) $ 16 07/20/2022 D 86,250 ( 3 ) 04/22/2030 Common Stock 86,250 ( 2 ) 0 D Stock Option (right to buy) $ 29.83 07/20/2022 D 90,000 ( 4 ) 01/31/2031 Common Stock 90,000 ( 2 ) 0 D Stock Option (right to buy) $ 9.48 07/20/2022 D 108,750 ( 5 ) 01/31/2032 Common Stock 108,750 ( 2 ) 0 D Stock Option (right to buy) $ 4.36 07/20/2022 A 207,500 ( 6 ) 07/19/2032 Common Stock 207,500 ( 2 ) 207,500 D Stock Option (right to buy) $ 4.36 07/20/2022 A 86,250 ( 6 ) 07/19/2032 Common Stock 86,250 ( 2 ) 86,250 D Stock Option (right to buy) $ 4.36 07/20/2022 A 90,000 ( 7 ) 07/19/2032 Common Stock 90,000 ( 2 ) 90,000 D Stock Option (right to buy) $ 4.36 07/20/2022 A 108,750 ( 7 ) 07/19/2032 Common Stock 108,750 ( 2 ) 108,750 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Piscitelli Dominic C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR SOUTH SAN FRANCISCO, CA94080 Chief Financial Officer Signatures /s/ Christian Kuhlen, attorney-in-fact 07/21/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Twenty five percent (25%) of the shares subject to the option vested on September 10, 2020, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. ( 2 )On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. ( 3 )Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. ( 4 )Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter. ( 5 )Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter. ( 6 )One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. ( 7 )Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.